SUBSCRIBE
SUBSCRIBE
News   Drug Development

GlaxoSmithKline Study Shows Its Cancer Shot Beats Merck & Co., Inc.'s (JOBS)

May 8, 2009 | 
1 min read
Bookmark and Share

Reuters -- GlaxoSmithKline's vaccine Cervarix produces a more powerful immune response against a sexually transmitted virus that causes cervical cancer than Merck & Co's rival Gardasil, research showed on Friday.

Clinical research Postmarket research
Merck & Co. GlaxoSmithKline
MORE ON THIS TOPIC
IN PARTNERSHIP WITH IQVIA
Understanding the FDA’s AI Guidance in Pharmacovigilance
July 1, 2025
 · 
1 min read
 · 
Lori Ellis
Hand holding a nasal spray bottle against a white background
Psychedelics
Beckley’s Psychedelic Nasal Spray Clears Phase II Depression Study
July 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Collage with halftone hands putting puzzle together. Teamwork concept vector pop art retro style illustration. Partnership and relationship design element for infographic, poster, website
Rare diseases
FDA Signs Off on Neurogene’s ‘Best-Case Scenario’ Pivotal Study Design for Rett Syndrome
July 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Megaphone with stethoscope isolated on orange background. 3d illustration
Obesity
Protagonist Enters Obesity Fray With Triple-G Pill, Eyeing 2026 Clinical Start
July 1, 2025
 · 
2 min read
 · 
Tristan Manalac